

# The risk of stroke recurrence in patients with atrial fibrillation and reduced ejection fraction

European Stroke Journal  
1–7

© European Stroke Organisation 2023

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/23969873231177625

journals.sagepub.com/home/eso



## RAF and RENO-EXTEND Investigators\*

### Abstract

**Background:** Atrial fibrillation (AF) and congestive heart failure often coexist due to their shared risk factors leading to potential worse outcome, particularly cerebrovascular events. The aims of this study were to calculate the rates of ischemic and severe bleeding events in ischemic stroke patients having both AF and reduced ejection fraction (rEF) ( $\leq 40\%$ ), compared to ischemic stroke patients with AF but without rEF.

**Methods:** We performed a retrospective analysis that drew data from prospective studies. The primary outcome was the composite of either ischemic (stroke or systemic embolism), or hemorrhagic events (symptomatic intracranial bleeding and severe extracranial bleeding).

**Results:** The cohort for this analysis comprised 3477 patients with ischemic stroke and AF, of which, 643 (18.3%) had also rEF. After a mean follow-up of  $7.5 \pm 9.1$  months, 375 (10.8%) patients had 382 recorded outcome events, for an annual rate of 18.0%. While the number of primary outcome events in patients with rEF was 86 (13.4%), compared to 289 (10.2%) for the patients without rEF; on multivariable analysis rEF was not associated with the primary outcome (OR 1.25; 95% CI 0.84–1.88). At the end of follow-up, 321 (49.9%) patients with rEF were deceased or disabled (mRS  $\geq 3$ ), compared with 1145 (40.4%) of those without rEF; on multivariable analysis, rEF was correlated with mortality or disability (OR 1.35; 95% CI 1.03–1.77).

**Conclusions:** In patients with ischemic stroke and AF, the presence of rEF was not associated with the composite outcome of ischemic or hemorrhagic events over short-term follow-up but was associated with increased mortality or disability.

### Keywords

Acute stroke, atrial fibrillation, congestive heart failure

Date received: 10 March 2023; accepted: 5 May 2023

## Introduction

Atrial fibrillation (AF) is the most common arrhythmia observed in clinical practice, accounting for approximately one-third of in-hospital admissions due to cardiac rhythm disturbances, the most common cardiac arrhythmia in the elderly, and is recognized as a major risk factor for stroke.<sup>1</sup> The coupling of AF and congestive heart failure (CHF) was demonstrated over 70 years ago.<sup>2</sup> Both conditions often coexist due to their shared risk factors, including hypertension, diabetes mellitus, ischemic heart disease, obesity, and valvular disease. The development of AF in patients with CHF has been reported to be associated with worse prognosis. Likewise, the development CHF in AF patients has also been associated with worse prognosis,<sup>1</sup> and is significantly

associated with all-cause mortality.<sup>3</sup> Furthermore, an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Study identified CHF as an independent predictor of all-cause mortality in AF patients and the strongest predictor of cardiac death.<sup>4</sup> Regarding the risk of stroke, Sartipy et al.<sup>5</sup> reported that in patients with reduced ejection fraction (rEF) this risk combined with death was higher in AF patients, compared to

\*Complete list of Investigators on Supplemental material.

### Corresponding author:

Maurizio Paciaroni, Santa Maria della Misericordia Hospital, University of Perugia, Via G. Dottori 1, Perugia, Umbria 06100, Italy.

Email: maurizio.paciaroni@unipg.it

sinus rhythm patients (HR 1.19; 95% CI 1.14–1.26). Furthermore, current risk stratification schemes for AF focus on preventing stroke and systemic embolism by identifying those patients having major risk, that would require oral anticoagulation. The most commonly used score in this setting is the CHA<sub>2</sub>DS<sub>2</sub>-VASc score which incorporates a history of CHF as a risk marker.<sup>6</sup> However, a meta-analysis has reported a higher risk of mortality in patients with AF and rEF, compared to those with AF and preserved ejection fraction; the risks of stroke were reported to be similar in the two groups.<sup>1</sup> Another meta-analysis of the subgroup of patients with CHF enrolled in the phase III non-vitamin K antagonist (NOAC) trials, reported that the rates of systemic embolism, bleeding, or death, while on NOACs, were comparable to those of patients without CHF on NOACs.<sup>7</sup>

In light of the above, the aims of this study were to calculate and compare the rates of ischemic and severe bleeding events in ischemic stroke patients having both AF with reduced ejection fraction (rEF) ( $\leq 40\%$ ), and ischemic stroke patients with AF but without rEF. Moreover, functional clinical outcomes were assessed for both groups.

### Study design and study population

We performed a retrospective study based on pooled individual data from an international collaboration of investigator-initiated prospective cohort studies. The following studies were included: the multicenter cohort studies Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation (RAF and RAF-NOAC; 29 centers in Europe, Asia, and North America), Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes (RAF-Posterior; 19 stroke units in Europe, North America, and Asia), and the Recurrent Ischemic Stroke and Bleeding in Patients with Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With NOACs (RENO-EXTEND; 43 centers in Europe and United States).

Details regarding the included studies can be obtained from the previously published studies.<sup>8–11</sup>

### Data collection

Data was collected as described in prior publications: local investigators filled in standardized forms with predefined variables using individual patient data from their respective study databases. Completed forms were sent to the coordinating center in Perugia, Italy, where the pooled analysis was performed.<sup>8–11</sup>

### Baseline data

The following baseline variables were investigated: age, sex; antithrombotic treatment (no treatment, antiplatelet

agents, vitamin K antagonist (VKA), or NOAC including type of NOAC) before and after index event. NOAC therapy was defined as: apixaban 2.5 mg or 5 mg twice daily; dabigatran 110 mg or 150 mg twice daily; edoxaban 30 mg or 60 mg once daily; or rivaroxaban 15 mg or 20 mg once daily. VKA therapy was defined as treatment with acenocoumarol/warfarin. The choice of treatment was decided by the treating physician in accordance with international guidelines.

On admission, stroke severity was assessed using the National Institute of Health Stroke Scale (NIHSS).

The following risk factors were collected: history of hypertension (blood pressure of  $\geq 140/90$  mmHg at least twice before stroke or treatment with antihypertensive drugs), history of diabetes mellitus (fasting glucose level  $\geq 126$  mg/dL preprandial on two measurements, glucose level  $\geq 200$  mg/dL post-prandial, or HbA1c  $\geq 6.5\%$ , or diabetic treatment), current cigarette smoking, hyperlipidemia (total cholesterol  $\geq 200$  mg/dL or triglyceride  $\geq 140$  mg/dL or lipid lowering therapy), history of symptomatic ischemic heart disease (myocardial infarction, angina, existence of multiple lesions on thallium heart isotope scan, or evidence of coronary disease on coronary angiography), current alcohol abuse ( $\geq 300$  g per week), treatment with statins after the index stroke or previous stroke/transient ischemic attack (TIA). On admission, a cerebral CT without contrast or an MRI scan was performed on all patients to exclude intracranial hemorrhage. We assessed the presence of white matter changes (leukoaraiosis defined on the first computed tomography examination as ill-defined and moderately hypodense areas of  $\geq 5$  mm according to published criteria). Leukoaraiosis in the deep white matter was dichotomized into absent versus present (mild, moderate, or severe).<sup>12</sup>

AF was classified as paroxysmal when episodes terminated spontaneously within 7 days.

The CHA<sub>2</sub>DS<sub>2</sub>-VASc score (2 points for history of stroke or age  $> 75$  years and 1 point each for CHF, hypertension, diabetes mellitus, vascular disease, age between 65 and 74 years, and female sex) was calculated before and after the index event.<sup>6</sup>

Any concurrent antiplatelet use prior to and after the index stroke was also recorded. Patients treated with antiplatelets, had been taking aspirin 75–300 mg per day or clopidogrel 75 mg per day.

### Classification of ejection fraction

Transthoracic echocardiogram (TTE) was performed within 7 days of stroke onset by an in-house cardiologist using a standardized protocol. Patients were imaged while in a left lateral decubitus position. Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal (standard long- and short-axis images) and apical views (standard long-axis, two- and four-chamber images). Standard two-dimensional and color Doppler data, triggered

to the QRS complex, were saved in cine loop format. Pulsed and continuous wave Doppler data were also stored digitally. On TTE, increased end-diastolic diameter and volume (LV diameter over 60 mm or 32 mm/m<sup>2</sup> with LV volume exceeding 97 mL/m<sup>2</sup>) and end-systolic diameter and volume (LV diameter greater than 45 mm or 25 mm/m<sup>2</sup> with LV volume over 43 mL/m<sup>2</sup>) were measured. Ejection fraction was calculated using the modified Simpson or the modified Quinones method.<sup>13</sup> Patients were classified as being with rEF ( $\leq 40\%$ ) or without rEF ( $>40\%$ ).<sup>14</sup>

### Outcome evaluation

Patients were followed-up prospectively either in person or by telephone interviews over a duration of at least 3 months from the time of the index event. The initiation of oral anticoagulation followed international guideline recommendations.<sup>15</sup>

The primary outcome was the composite of ischemic stroke, systemic embolism, intracranial bleeding, and major extracranial bleeding. Recurrent stroke was defined as the sudden onset of a new focal neurological deficit of vascular origin in a site consistent with the territory of a major cerebral artery and was categorized as ischemic or hemorrhagic. Regarding systemic embolism, it was defined as an acute vascular occlusion of an extremity or organ confirmed by imaging, surgery, or autopsy. Intracranial bleeding was defined as a spontaneous hemorrhagic stroke (intraparenchymal bleeding), subdural, or subarachnoid hemorrhage, whereas traumatic intracranial bleeding was not considered as an outcome event. Major extracranial bleeding was defined as either a reduction in the hemoglobin level of 2 g/dL or more, the requirement of a blood transfusion of at least two units, or symptomatic bleeding in either a critical area or organ such as intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome.

Death was recorded and functional recovery was assessed by the modified Rankin Scale (mRS), dichotomizing between functional independence (mRS score 0–2) and disability (mRS score  $\geq 3$ ).<sup>16</sup> Follow-up visits and outcome adjudication were performed by local investigators, in a non-blinded manner.

### Statistical analysis

For patients with or without outcome events, differences in clinical characteristics and risk factors were calculated using the  $\chi^2$  test of proportions (with a two-sided  $\alpha$  level of 5%). To this regard, 95% confidence intervals (CIs) were calculated for odds ratio (OR). Moreover, multivariable logistic regression analysis was performed to identify independent associations for outcome events and the variables included in this analysis were the following: age, sex, hypertension, diabetes, mellitus, hyperlipidemia, current

alcohol abuse, current smoking habit, paroxysmal AF, history of stroke or TIA, history of myocardial infarction, therapy with oral anticoagulants, therapy with statins, presence of leukoaraiosis, antiplatelet therapy in addition to oral anticoagulant therapy after the index stroke and rEF. For mortality and disability, the same analyses were performed. Furthermore, for outcome events, survival and empirical cumulative hazard functions were estimated via the Kaplan-Meier estimator for the two groups. Patients were censored at the time of an outcome event or death.

In order to compare the risk of outcome events in those patients who had rEF treated with NOACs, with patients who had rEF treated with vitamin K antagonist (VKA), the relation between the survival function and the set of explanatory variables was calculated by Cox proportional hazard model.

Data were analyzed using the SPSS/PC Win Package 25.0.

### Results

The final cohort comprised of 3477 of the original 3869 patients (89.9%) with ischemic stroke and AF from the pooled data sets: 252 patients were excluded due to duplication (patients present in more than one database of the cohort populations considered) and 140 had not undergone a TTE during hospitalization. In this cohort, 643 patients (18.3%) had rEF and their characteristics are summarized in Table 1. Independent associations of rEF included history of myocardial infarction (OR 3.74; 95% CI 2.79–5.02), alcohol abuse (OR 2.18; 95% CI 1.40–3.38), and diabetes mellitus (OR 1.37; 95% CI 1.04–1.80) whereas, the presence of paroxysmal AF was inversely associated with rEF (OR 0.35; 95% CI 0.27–0.47).

#### *Factors associated with ischemic and bleeding events*

After a mean follow-up of  $7.5 \pm 9.1$  months (2173 patient-years), in 375 patients (10.8%) 382 outcome events were recorded, corresponding to an annual rate of 18.0%. The following outcome events were observed: 199 ischemic strokes, 31 systemic embolisms, 79 intracranial bleedings, and 73 major extracranial bleedings. The demographic and clinical characteristics of the patients with or without outcome events are summarized in Tables S1–S3.

The number of recorded outcome events in patients with rEF was 86 (13.4%) combined, 58 (9.0%) ischemic, and 29 (4.5%) hemorrhagic compared to patients without rEF, where there were 289 (10.2%) combined events, 172 (6.1%) ischemic events, and 123 (4.4%) hemorrhagic events (OR 1.36; 95% CI 1.05–1.64, OR 1.53; 95% CI 1.12–2.09, and OR 1.04; 95% CI 0.69–1.57, respectively) (Table 2).

Factors independently associated with the different outcomes are reported in Table 3; rEF was not associated with

**Table 1.** Characteristics of the patients with and without ejection fraction (EF)  $\leq 40\%$  and functional outcome.

	EF $\leq 40\%$ (N=643)	EF $> 40\%$ (N=2834)	p
Age, years – mean (median)	77.2 $\pm$ 10.6 (79)	76.1 $\pm$ 9.6 (77)	0.05
Male sex	328 (51.0%)	1340 (47.3%)	0.09
NIHSS on admission – mean (median)	8.5 $\pm$ 6.3 (6)	8.4 $\pm$ 6.8 (7)	0.8
Diabetes mellitus	197 (30.6%)	649 (22.9%)	<0.0001
Hypertension	535 (83.2%)	2264 (79.9%)	0.08
Hyperlipidemia	284 (44.2%)	1125 (39.7%)	0.03
Paroxysmal AF	195 (30.3%)	1351 (47.7%)	<0.0001
History of stroke/TIA	206 (32.0%)	844 (29.8%)	0.2
Current smoker	118 (18.3%)	567 (20.0%)	0.3
Alcoholism	71 (11.0%)	186 (6.6%)	<0.0001
History of myocardial infarction	215 (33.4%)	406 (14.3%)	<0.0001
Leukoaraiosis	385 (59.9%)	1524 (53.8%)	0.005
CHA <sub>2</sub> DS <sub>2</sub> VASc $> 3$	597 (92.8%)	2364 (83.4%)	<0.0001
mRS $\geq 3$ at the end of follow up	321 (49.9%)	1145 (40.4%)	<0.0001
Mortality at the end of follow up	88 (13.7%)	276 (9.7%)	0.005

**Table 2.** Outcome events in patients with or without ejection fraction (EF)  $\leq 40\%$ .

	EF $\leq 40\%$ (N=643)	EF $> 40\%$ (N=2834)	Odds ratio (95% CI)
Combined outcome events*	86 (13.4%)	289 (10.2%)	1.36 (1.05–1.64) adj. 1.25 (0.84–1.88)
Ischemic outcome events	58 (9.0%)	172 (6.1%)	1.53 (1.12–2.09) adj. 1.42 (0.87–2.02)
Hemorrhagic outcome events	29 (4.5%)	123 (4.4%)	1.04 (0.69–1.57) adj. 0.97 (0.64–1.49)

adj: adjusted.

\*Ischemic and hemorrhagic outcome events.

**Table 3.** Factors independently associated with the different outcomes.

	OR (95% confidence interval)
Combined outcome*	
Diabetes mellitus	1.58 (1.11–2.26)
Antiplatelet therapy associated with oral anticoagulant	1.75 (1.14–2.69)
Oral anticoagulant	0.46 (0.32–0.67)
Ischemic outcome	
Diabetes mellitus	1.63 (1.05–2.54)
Antiplatelet therapy associated with oral anticoagulant	2.39 (1.44–3.98)
Paroxysmal atrial fibrillation	0.61 (0.39–0.97)
Hemorrhagic outcome	
Antiplatelet therapy associated with oral anticoagulant	1.82 (1.19–2.49)

\*Ischemic and hemorrhagic outcome events.

any outcome: OR 1.25; 95% CI 0.84–1.88 for combined outcome, OR 1.42; 95% CI 0.87–2.02 for ischemic outcome, and OR 0.97; 95% CI 0.64–1.49 for hemorrhagic outcome.


The Kaplan-Meier curves that compared the overall outcome events in those patients with and without rEF are shown in Figure 1.

### Rates and associated factors of mortality or disability

Regarding functional outcome, at the end of follow-up, 1466 (42.2%) patients were deceased or disabled (mRS  $\geq 3$ ), whereas 364 (10.5%) were deceased. Comparison-wise, 321 (49.9%) with rEF were deceased or disabled, compared to 1145 (40.4%) without (OR 1.47; 95% CI 1.24–1.75), while 88 (13.7%) with rEF were deceased, compared to 276 (9.7%) without (OR 1.47; 95% CI 1.14–1.90). On multi-variable analysis, rEF was correlated with mortality or disability (OR 1.35; 95% CI 1.03–1.77) but not with mortality (OR 1.13; 95% CI 0.69–1.87).

### Rates of ischemic and bleeding events in patients with rEF treated with NOACS or with VKA

The treatment approaches for secondary stroke prevention in patients with rEF were the following: 421 (65.5%) NOACs, 129 (20.1%) VKA, and 93 (14.5%) received no



**Figure 1.** Cumulative risk of combined, ischemic, or hemorrhagic endpoint events in patients with and without reduced ejection fraction.

oral anticoagulants. The demographic and clinical characteristics of the patients treated with NOACs or VKA are summarized in Table S4. The recorded outcome events in patients treated with NOACs were 46 (10.9%) combined, 32 (7.6%) ischemic, and 14 (3.3%) hemorrhagic compared to patients treated with VKA where there were 25 (19.4%) combined events, 17 (13.2%) ischemic events, and 8 (6.2%) hemorrhagic events (OR 0.51; 95% CI 0.30–0.87, OR 0.54; 95% CI 0.29–1.01, and OR 0.46; 95% CI 0.19–1.09, respectively). The Cox regression curve analysis that compared the overall outcome events in those patients treated with NOACs or VKA is reported in Figure 2. Within this analysis, VKA was associated with a non-statistically significant increase in combined outcome events compared to NOACs (HR 1.65; 95% CI, 0.95–2.86;  $p=0.07$ ). Finally, of those 93 patients who had not received oral anticoagulants, 14 (15.1%) had combined events, 9 (9.7%) ischemic events, and 5 (5.4%) hemorrhagic events while 37 (39.8%) were deceased.


## Discussion

In this pooled retrospective analysis that drew upon prospective cohort data, about 18% of the patients with ischemic stroke and AF had rEF, and the latter was associated with a history of myocardial infarction, diabetes mellitus, and alcohol abuse, while it was inversely associated with the presence of paroxysmal AF; rEF was not associated with the composite outcome of ischemic or hemorrhagic events, but was associated with mortality or disability.

Regarding etiology, rEF has been reported to be a possible consequence of AF due to rapid pulse (tachycardia) that generally leads to atrial morphological changes with subsequent cardiomyopathy<sup>17</sup> and reduced left atrial “kick.”<sup>18</sup> About 70% of the rEF patients included in our study had persistent or permanent AF, compared to about 52% of patients without rEF. In fact, persistent or

permanent AF have been reported to be more commonly associated with cardiac structural degeneration, compared to paroxysmal AF. This cardiac structural degeneration has been associated with subsequent stroke risk.<sup>19</sup> Conversely, structural changes associated with chronic CHF make AF much more prevalent.<sup>17</sup>

Concerning functional outcome, patients with rEF had index strokes with similar severities, measured with NIHSS on admission, compared to those patients without rEF. Furthermore, the risks of either embolic recurrences or hemorrhagic complications were similar in patients with or without rEF. Despite the above findings, patients with rEF were more likely to be deceased or disabled at the end of follow-up. The principal cause of this worse functional outcome, might plausibly be explained by a progression of heart failure over time. To this regard, a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD)



**Figure 2.** Cumulative risk of combined endpoint events in patients with reduced ejection fraction treated with NOAC or with vitamin-K antagonist.



trial, which had enrolled 6500 patients with left ventricular ejection fraction  $\leq 35\%$ , reported that the presence of AF was an independent predictor for both progressive pump failure, and the combined end point of death or hospitalization for heart failure.<sup>20</sup>

As for treatment, a meta-analysis reported that in patients with AF and CHF, NOACs significantly reduced the risks of stroke, systemic embolism, and bleeding events, including major bleeding and intracranial hemorrhage, compared with warfarin. No interactions in the efficacy or safety profile of NOACs compared with warfarin were observed in patients either with or without heart failure.<sup>7</sup> In our study, the risk of combined events (ischemic and hemorrhagic) was 10.9% in patients having AF and reduced eEF and prescribed with NOACs, compared to 19.4% for those prescribed with warfarin. From Cox regression analysis, this difference did not result being statistically significant, despite a clear trend in favor of NOACs. Our study, however, was not designed to evaluate this aim.

The strengths of our study included its adequate sample size and its prospective design of the included studies. Moreover, our findings reflect real-life experiences and may provide critical observational information. In fact, in view of a lack of any randomized data, the use of predictive factors to assess prognosis has been shown to improve quality of life, as well as long-term outcome.

Our study had several limitations. First, the reported results could have been influenced by unmeasured confounders which could not be overcome in adjusted statistical models which were used to reduce their impact. Second, we did not collect data regarding any treatment for heart failure prescribed for each patient during follow-up, including therapies for rate control or rhythm restoration and rhythm control, ablation, or pacemaker. Third, we did not collect data on patients with a history of heart failure but with preserved ejection fraction, this is because we had dichotomized the cohort into patients with or without rEF. To this regard, studies have reported differing outcomes in patients with heart failure and rEF, compared to those with heart failure and preserved ejection fraction.<sup>1,21</sup> Fourth, 4% of the patients were excluded because of lacking TTE, and these patients might have been severely disabled or terminal patients, which would have affected the composite outcome. Finally, the duration of follow-up was limited to a mean of 7.5 months which might not have been long enough to evidence a difference in stroke recurrence between the two groups, as there was evidence of a trend toward higher vascular events in the rEF group.

In conclusion, our study results suggest that, in patients with ischemic stroke and AF, the presence of rEF was not associated with combined, ischemic, or hemorrhagic events over short-term follow-up but was associated with mortality or disability at the end of follow-up.

### Acknowledgements

None

### Declaration of conflicting interests

The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M. Paciaroni received honoraria as a member of the speaker bureau of Sanofi-Aventis, Bayer, Bristol Meyer Squibb, Daiiki Sankyo and Pfizer.

### Funding

The author received no financial support for the research, authorship, and/or publication of this article.

### Ethical approval

The studies had been approved by the pertinent institutional review boards if required.

### Informed consent

Informed consent had been obtained according to local requirements.

### Guarantor

Maurizio Paciaroni

### Contributorship

Maurizio Paciaroni conceived the study and wrote the first draft of the manuscript. All Investigators were involved in protocol development, gaining ethical approval, patient recruitment, and data analysis. All Investigators reviewed and edited the manuscript and approved the final version of the manuscript.

### Supplemental material

Supplemental material for this article is available online.

### References

1. Kotecha D, Chudasama R, Lane DA, et al. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. *Int J Cardiol* 2016; 203: 660–666.
2. Phillips E and Levine SA. Auricular fibrillation without other evidence of heart disease. *Am J Med* 1949; 7: 478–589.
3. Mamas MA, Caldwell JC, Chacko S, et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. *Eur J Heart Fail* 2009; 11: 676–683.
4. Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from randomized evaluation of long-term anticoagulant therapy (RE-LY) study. *Circulation* 2013; 128: 2192–2201.
5. Sartipy U, Dahlström U, Fu M, et al. Atrial fibrillation in heart failure with preserved, mid-range and reduced ejection fraction. *JACC Heart Fail* 2017; 5: 565–574.
6. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart survey on atrial fibrillation. *Chest* 2010; 137: 263–272.

7. Savarese G, Giugliano RP, Rosano GMC, et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. *JACC Heart Fail* 2016; 4: 870–880.
8. Paciaroni M, Caso V, Agnelli G, et al. Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants: the RENO-EXTEND study. *Stroke* 2022; 53: 2620–2627.
9. Paciaroni M, Agnelli G, Giustozzi M, et al. Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. *Eur Stroke J* 2020; 5: 374–383.
10. Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study. *J Am Heart Assoc* 2017; 6: e007034.
11. Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. *Stroke* 2015; 46: 2175–2182.
12. Wahlund LO, Barkhof F, Fazekas F, et al.; European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. *Stroke* 2001; 32: 1318–1322.
13. Gimelli A, Lancellotti P, Badano LP, et al. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI). *Eur Heart J* 2014; 35: 3417–3425.
14. Murphy SP, Ibrahim NE and Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. *JAMA* 2020; 324: 488–504.
15. Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. *Eur Stroke J* 2019; 4: 198–223.
16. de Haan R, Limburg M, Bossuyt P, et al. The clinical meaning of Rankin “handicap” grades after stroke. *Stroke* 1995; 26: 2027–2030.
17. Anter E, Jessup M and Callans DJ. Atrial fibrillation and heart failure. Treatment considerations for a dual epidemic. *Circulation* 2009; 119: 2516–2525.
18. Kurapati R, Heaton J and Lowery DR. Atrial kick. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022.
19. Manolis AS, Manolis TA, Manolis AA, et al. Atrial fibrillation-induced tachycardio-myopathy and heart failure: an underappreciated and elusive condition. *Heart Fail Rev* 2022; 27: 2119–2135.
20. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: studies of left ventricular dysfunction. *J Am Coll Cardiol* 1998; 32: 695–703.
21. Liang M, Bian B and Yang Q. Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: a systemic review and meta-analysis. *Clin Cardiol* 2022; 45: 5–17.

## **Supplemental material**



## List of RAF and RENO-Extend Investigators

Maurizio Paciaroni<sup>1</sup>, MD; Giancarlo Agnelli<sup>1</sup>, MD; Valeria Caso<sup>1</sup>, PhD; Cecilia Becattini<sup>1</sup>, MD; Maria Giulia Mosconi<sup>1</sup> MD, Michela Giustozzi<sup>1</sup>, MD; Georgios Tsivgoulis<sup>2</sup>, MD; David Julian Seiffge<sup>3,4</sup>, MD; Stefan T. Engelter<sup>3</sup>, MD; Philippe Lyrer<sup>3</sup>, MD, Alexandros A. Polymeris<sup>3</sup>, MD; Tolga Dittrich<sup>3</sup>, MD; Annaelle Zietz<sup>3</sup>, MMed; Jukka Putaala<sup>5</sup>, MD; Daniel Strbian<sup>5</sup>, PhD; Liisa Tomppo<sup>5</sup>, MD; Patrik Michel<sup>6</sup>, MD; Davide Strambo<sup>6</sup>, MD; Alexander Salerno<sup>6</sup>, MD; Suzette Remillard<sup>6</sup>, PNC; Manuela Buehrer<sup>6</sup>, PNC; Odessa Bavaud<sup>6</sup>, CORP; Peter Vanacker<sup>7,8,9</sup>, PhD; Susanna M. Zuurbier<sup>7,8</sup>, MD; Laetitia Yperzeele<sup>7,8</sup>, PhD; Caroline M.J. Loos<sup>7,8</sup>, PhD; Manuel Cappellari<sup>10</sup>, MD; Andrea Emiliani<sup>10</sup>, MD; Marialuisa Zedde<sup>11</sup>, MD; Azmil H. Abdul-Rahim<sup>12,13</sup>, MD; Jesse Dawson<sup>13</sup>, MD; Robert Cronshaw<sup>13</sup>, MB BChir; Erika Schirinzi<sup>14</sup>, MD; Massimo Del Sette<sup>14</sup>, MD; Christoph Stretz<sup>15</sup>, MD; Narendra Kala<sup>15</sup>, MD; Michael Reznik<sup>15</sup>, MD; Ashley Schomer<sup>15</sup>, MD; Brian Mac Grory<sup>15,16</sup>, MB, BCh, BAO, MRCP; Mahesh Jayaraman<sup>15</sup>, MD; Shadi Yaghi<sup>15</sup>, MD; Karen L. Furie<sup>15</sup>, MD, MPH; Luca Masotti<sup>17</sup>, MD; Elisa Grifoni<sup>17</sup>, MD; Danilo Toni<sup>18</sup>, MD; Angela Risitano<sup>18</sup>, MD; Anne Falcou<sup>19</sup>, MD; Luca Petraglia<sup>18</sup>, MD; Enrico Maria Lotti<sup>20</sup>, MD; Marina Padroni<sup>21</sup>, MD; Lucia Pavolucci<sup>20</sup>, MD; Piergiorgio Lochner<sup>22</sup>, MD; Giorgio Silvestrelli<sup>23</sup>, PhD; Alfonso Ciccone<sup>23</sup>, MD; Andrea Alberti<sup>1</sup>, MD; Michele Venti<sup>1</sup>, PhD; Ilaria Leone De Magistris<sup>1</sup>, MD; Virginia Cancelloni<sup>1</sup>, MD; Odysseas Kargiotis<sup>24</sup>, MD; Alessandro Rocco<sup>25</sup>, MD; Marina Diomedi<sup>25</sup>, MD; Simona Marcheselli<sup>26</sup>, MD; Pietro Caliandro<sup>27</sup>, MD; Aurelia Zauli<sup>28</sup>, MD; Giuseppe Reale<sup>28</sup>, MD; Marco Moci<sup>28</sup>, MD; Kateryna Antonenko<sup>4,29</sup>, MD; Eugenia Rota<sup>30</sup>, MD; Tiziana Tassinari<sup>31</sup>, MD; Valentina Saia<sup>31</sup>, PhD; Francesco Palmerini<sup>32</sup>, MD; Paolo Aridon<sup>33</sup>, PhD; Valentina Arnao<sup>34</sup>, PhD; Serena Monaco<sup>34</sup>, MD; Salvatore Cottone<sup>34</sup>, MD; Antonio Baldi<sup>35</sup>, MD; Cataldo D'Amore<sup>35</sup>, MD; Walter Ageno<sup>36</sup>, MD; Samuela Pegoraro<sup>36</sup>, MD; George Ntaios<sup>37</sup>, MD; Dimitrios Sagris<sup>37</sup>, MD; Sotirios Giannopoulos<sup>38</sup>, MD; Maria Kosmidou<sup>38</sup>, MD; Evangelos Ntais<sup>38</sup>, MD; Michele Romoli<sup>39</sup>, MD; Leonardo Pantoni<sup>40</sup>, MD, PhD; Silvia Rosa<sup>41</sup>, MD; Pierluigi Bertora<sup>40</sup>, MD; Alberto Chiti<sup>42</sup>, MD; Isabella Canavero<sup>43,44</sup>, MD; Carlo Emanuele Saggese<sup>45</sup>, MD; Maurizio Plocco<sup>45</sup>, MD; Elisa Giorli<sup>46</sup>, MD; Lina Palaiodimou<sup>2</sup>, MD; Eleni

Bakola<sup>2</sup>, MD; Fabio Bandini<sup>47</sup>, MD; Antonio Gasparro<sup>48</sup>, MD; Valeria Terruso<sup>48</sup>, MD; Marina Mannino<sup>48</sup>, MD; Alessandro Pezzini<sup>49</sup>, MD; Andrea Morotti<sup>49</sup>, MD; Mauro Magoni<sup>49</sup>, MD; Raffaele Ornello<sup>50</sup>, MD; Simona Sacco<sup>50</sup>, MD; Nemanja Popovic<sup>51</sup>, MD; Umberto Scoditti<sup>52</sup>, MD; Antonio Genovese<sup>52</sup>, MD; Licia Denti<sup>53</sup>, MD; Yuriy Flomin<sup>54</sup>, MD; Michelangelo Mancuso<sup>55</sup>, MD; Elena Ferrari<sup>55</sup>, MD; Maria Chiara Caselli<sup>55</sup>, MD; Leonardo Ulivi<sup>55</sup>, MD; Nicola Giannini<sup>55</sup>, MD; Kostantinos Vadikolias<sup>56</sup>, MD; Chrysoula Liantinioti<sup>2</sup>, MD; Maria Chondrogianni<sup>2</sup>, MD; Monica Carletti<sup>10</sup>, MD; Efstathia Karagkiozi<sup>37</sup>, MD; George Athanasakis<sup>37</sup>, MD; Kostantinos Makaritsis<sup>37</sup>, MD; Alessia Lanari<sup>57</sup>, MD, PhD; Turgut Tatlisumak<sup>58</sup>, MD; Monica Acciarresi<sup>59</sup>, MD; Vieri Vannucchi<sup>16</sup>, MD; Gianni Lorenzini<sup>60</sup>, MD; Rossana Tassi<sup>61</sup>, MD; Francesca Guideri<sup>61</sup>, MD; Maurizio Acampa<sup>61</sup>, MD; Giuseppe Martini<sup>61</sup>, MD; Sung-Il Sohn<sup>62</sup>, MD, PhD; Nicola Mumoli<sup>63</sup>, MD; Prasanna Tadi<sup>64</sup>, MD; Federica Letteri<sup>18</sup>, MD; Miriam Maccarrone<sup>65</sup>, MD; Franco Galati<sup>66</sup>, MD; Cindy Tiseo<sup>50</sup>, MD; Vanessa Gourbali<sup>67</sup>, MD; Panagiotis Halvatsiotis<sup>68</sup>, MD; Giovanni Orlandi<sup>55</sup>, MD; Martina Giuntini<sup>69</sup>, MD; Francesco Corea<sup>59</sup>, MD, PhD; Marta Bellesini<sup>36</sup>, MD; Mario Maimone Baronello<sup>34</sup>, MD; Theodore Karapanayiotides<sup>70</sup>, MD, PhD; Christina Rueckert<sup>71</sup>, MD; Laszló Csiba<sup>72</sup>, MD; Lilla Szabó<sup>72</sup>, MD; Alberto Rigatelli<sup>10</sup>, MD; Davide Imberti<sup>73</sup>, MD; Dorjan Zabzuni<sup>73</sup>, MD; Alessio Pieroni<sup>74</sup>, MD; Kristian Barlinn MD<sup>75</sup>, Lars-Peder Pallesen MD<sup>75</sup>, Jessica Barlinn MD<sup>75</sup>; Boris Doronin<sup>76</sup>, MD; Vera Volodina<sup>76</sup>, MD; Dirk Deleu<sup>77</sup>, MD, PhD, FRCP; Bruno Bonetti<sup>10</sup>, MD, Cesare Porta<sup>63</sup>, MD, Luana Gentile<sup>18</sup>, MD, Ashraf Eskandari<sup>6</sup>, MD, Gian Marco De Marchis<sup>3</sup>, MD, MSc

- <sup>1</sup>Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Italy
- <sup>2</sup>Second Department of Neurology, “Attikon” University Hospital, National & Kapodistrian University of Athens, School of Medicine, Athens, Greece
- <sup>3</sup>Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Switzerland
- <sup>4</sup>Department of Neurology, Inselspital University Hospital and University of Bern, Switzerland
- <sup>5</sup>Department of Neurology, Helsinki University Hospital and Neurosciences University of Helsinki, Finland
- <sup>6</sup>Stroke Center, Neurology Service, Department of Clinical Neuroscience, Lausanne University Hospital and University of Lausanne, Switzerland
- <sup>7</sup>NeuroVascular Center and Stroke Unit Antwerp, Department of Neurology, Antwerp University Hospital, Antwerp, Belgium
- <sup>8</sup>Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium
- <sup>9</sup>Groeninge Hospital, Kortrijk, Belgium
- <sup>10</sup>Stroke Unit, DAI di Neuroscienze, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
- <sup>11</sup>Neurology Unit, AUSL - IRCCS of Reggio Emilia, Italy
- <sup>12</sup>School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom
- <sup>13</sup>Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
- <sup>14</sup>Struttura Complessa di Neurologia, Ente Ospedaliero Ospedali Galliera, Genoa, Italy
- <sup>15</sup>Department of Neurology, The Warren Alpert Medical School of Brown University, Providence, RI, USA
- <sup>16</sup>Department of Neurology, Duke University School of Medicine, Durham, North Carolina, USA
- <sup>17</sup>Internal Medicine, San Giuseppe Hospital, Empoli, Italy
- <sup>18</sup>Department of Human Neurosciences, Sapienza University of Rome, Italy
- <sup>19</sup>Stroke Unit – Emergency Department, Policlinico Umberto I, Rome, Italy
- <sup>20</sup>U.O. Neurologia Presidio Ospedaliero di Ravenna Azienda USL della Romagna, Italy
- <sup>21</sup>Neurology Unit, Azienda Ospedaliero-Universitaria Sant’Anna, Ferrara, Italy
- <sup>22</sup>Department of Neurology, Saarland University, Medical Center, Homburg, Germany
- <sup>23</sup>S.C. di Neurologia e S.S. di Stroke Unit, ASST di Mantova, Italy
- <sup>24</sup>Stroke Unit, Metropolitan Hospital, Piraeus, Greece
- <sup>25</sup>Stroke Unit, Department of Systems Medicine, University of Tor Vergata, Rome, Italy
- <sup>26</sup>Humanitas Clinical and Research Center - IRCCS, Rozzano, Milano, Italy
- <sup>27</sup>Neurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- <sup>28</sup>Department of Geriatrics, Neurosciences and Orthopedics, Università Cattolica del Sacro Cuore, Rome, Italy
- <sup>29</sup>Department of Neurology, Bogomolets National Medical University, Kyiv, Ukraine
- <sup>30</sup>S.C. Neurologia – Stroke Unit, Novi Ligure/Tortona, ASL Alessandria, Italy
- <sup>31</sup>Department of Neurology and Stroke Unit, Santa Corona Hospital, Pietra Ligure (Savona), Italy
- <sup>32</sup>Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy
- <sup>33</sup>Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Italy
- <sup>34</sup>Neurologia – Stroke Unit ARNAS Civico, Palermo, Italy
- <sup>35</sup>Stroke Unit, Ospedale di Portogruaro (Venice), Italy
- <sup>36</sup>Department of Medicine, University of Insubria, Ospedale di Circolo, Varese, Italy
- <sup>37</sup>Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
- <sup>38</sup>Department of Neurology, University of Ioannina School of Medicine, Ioannina, Greece
- <sup>39</sup>Neurology and Stroke Unit, Department of Neuroscience, Bufalini Hospital, Cesena, Italy
- <sup>40</sup>L. Sacco' Department of Biomedical and Clinical Sciences, University of Milan, Italy
- <sup>41</sup>Neurology Unit, ASST Fatebenefratelli – Sacco, Milan, Italy
- <sup>42</sup>Neurologia, Ospedale Apuano, Massa Carrara, Italy
- <sup>43</sup>Emergency Neurology, IRCCS Casimiro Mondino Foundation, Pavia, Italy
- <sup>44</sup>Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milano, Italy
- <sup>45</sup>Unità di Terapia Neurovascolare. Ospedale "Fabrizio Spaziani", Frosinone, Italy
- <sup>46</sup>Stroke Unit, Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy
- <sup>47</sup>Department of Neurology, Ospedale San Paolo, Savona, Italy
- <sup>48</sup>Neurologia, Ospedali Riuniti, Palermo, Italy
- <sup>49</sup>Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Italy
- <sup>50</sup>Neuroscience Section, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
- <sup>51</sup>Clinic of Neurology, University Clinical Center of Vòsvodina, University of Novi Sad, Serbia
- <sup>52</sup>Stroke Unit, Emergency Department, University of Parma, Italy
- <sup>53</sup>Stroke Unit - Dipartimento Geriatrico Riabilitativo – University of Parma, Italy
- <sup>54</sup>Stroke and Neurorehabilitation Unit MC ‘Universal Clinic ‘Oberig’ Kyiv, Ukraine
- <sup>55</sup>Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Italy
- <sup>56</sup>Department of Neurology, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
- <sup>57</sup>Neurology & Stroke Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- <sup>58</sup>Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
- <sup>59</sup>UO Gravi Cerebrolesioni, San Giovanni Battista Hospital, Foligno, Italy
- <sup>60</sup>SC Medicina e Chirurgia d’Accettazione e d’Urgenza, Ospedale Lotti Pontedera, Azienda USL Toscana Nordovest
- <sup>61</sup>Stroke Unit, AOU Senese, Siena, Italy
- <sup>62</sup>Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea
- <sup>63</sup>Internal Medicine Unit, Magenta Hospital, ASST Ovest Milanese, Magenta (MI), Italy
- <sup>64</sup>Program Director for Vascular Neurology (Stroke) Fellowship Program, Stroke/Vascular Neurologist Clinical, Associate Professor of Neurology, ABPN Diplomate, Board Certified in Neurology and Vascular Neurology, Geisinger Health System, USA

<sup>65</sup>Neurologia, Azienda Ospedaliera dell'Alto Adige, Italy

<sup>66</sup>Stroke Unit, Jazzolino Hospital, Vibo Valentia, Italy

<sup>67</sup>Department of Neurology, Evangelismos Hospital, Athens

<sup>68</sup>2<sup>nd</sup> Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Greece

<sup>69</sup>Neurologia, Ospedale Apuano, Massa Carrara, Italy

<sup>70</sup>2<sup>nd</sup> Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece

<sup>71</sup>Abteilung für Neurologie, Oberschwabenklinik gGmbH, Ravensburg, Germany

<sup>72</sup>Stroke Unit, University of Debrecen, Hungary

<sup>73</sup>Department of Internal Medicine, Ospedale Civile di Piacenza, Italy

<sup>74</sup>Stroke Unit, Azienda Ospedaliera Università di Padova, Padova, Italy

<sup>75</sup>Department of Neurology, Dresden University Stroke Center, Dresden, Germany

<sup>76</sup>Municipal Budgetary Healthcare Institution of Novosibirsk. City Clinical Hospital # 1. Novosibirsk (Russia) at the Novosibirsk State Medical University (Russia)

<sup>77</sup>Neurology, Hamad Medical Corporation, Doha, Qatar

**Disclosures of RAF and RENO-Extend Investigators:** M. Paciaroni received honoraria as a member of the speaker bureau of Sanofi-Aventis, Bayer, Bristol Meyer Squibb, Daiichi Sankyo and Pfizer. G. Agnelli received honoraria as a member of the speaker bureau of Boehringer Ingelheim and Bayer. C. Becattini received honoraria as a member of the speaker bureau of Bristol Meyer Squibb and Bayer. P. Michel received Research Grant by Swiss National Science Foundation and Swiss Heart Foundation; he received speaker fees by Bayer, Boehringer Ingelheim, Covidien, St. Jude Medical; he received honoraria as advisory relationship by Pierre-Fabre, Bayer, Bristol Meyer Squibb, Amgen, and Boehringer Ingelheim. J. Putaala has received personal fees from Boehringer Ingelheim, Bayer, and Portola. He has also received grants and personal fees from BMS-Pfizer and Abbott/St Jude Medical. T. Tatlisumak received honoraria as consultant or advisory relationship from Bayer, Boehringer Ingelheim, Bristol Meyer Squibb, Lumosa Pharm and Portola Pharma. G. Tsivgoulis has received funding for travel or speaker's honoraria from Bayer, Pfizer, and Boehringer Ingelheim. He has served on scientific advisory boards for Bayer, Boehringer Ingelheim, and Daiichi Sankyo. D. Toni has received personal fees from Abbott, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, and Pfizer. V. Caso received honoraria as a member of the speaker bureau of Boehringer Ingelheim, Bayer, and Daiichi Sankyo (all fees were paid to Associazione Ricerca Stroke, Umbria). She received honoraria as consultant or advisory board member of Boehringer Ingelheim, Bayer, Daiichi Sankyo, and Pfizer. W. Ageno has received speaker's honoraria from, and participated in scientific advisory boards for Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo and has received research support from

Bayer and Boehringer Ingelheim. J. Dawson reports honoraria as a member of the speaker bureau of Boehringer Ingelheim, Bayer, BMS, Daiichi Sankyo, Medtronic and Pfizer. He has also received research funding from Pfizer. G. Ntaios reports speaker fees/advisory board/ research support from Bayer, Pfizer, Boehringer Ingelheim and Elpen. All fees are paid to his institution. S. Sacco has received personal fees as speaker or advisor from Abbott, Allergan, Astra Zeneca, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Teva and research grants from Allergan, Novartis, and Uriach. P. Vanacker received honoraria as a member of the speaker bureau and as advisory board of Boehringer Ingelheim, Bristol Meyer Squibb, Daiichi Sankyo, Medtronic, EG and Pfizer. M. Del Sette has received honoraria for speaking from Bayer and Boehringer Ingelheim. M. Zedde received speaking and consulting fees from Daiichi Sankyo, Amicus Therapeutics, Sanofi Genzyme, Abbott, and Takeda. M. Cappellari has received consulting fees from Boehringer Ingelheim, Pfizer – BMS, and Daiichi Sankyo. Y. Flomin has received personal fees from Boehringer Ingelheim, Bayer and Takeda, grants, personal fees and nonfinancial support from Pfizer, personal fees and nonfinancial support from Sanofi Genzyme. E. Rota has received speaker fees from Bayer and Novartis. C. Stretz has received departmental funding from Massachusetts General Hospital/Boston Scientific for his site's participation in the Neuro Afib study. R. Ornello has received nonfinancial support from Novartis, Allergan, and Teva. S. Giannopoulos has received funding for travel from Bayer and speaker's honoraria from Pfizer. D. Strbian received honoraria from Portola and BMS for participation in scientific advisory board and unrestricted educational grant from Boehringer Ingelheim.

The other authors report no conflicts.



**Table S1.** Characteristics of the patients with combined event (ischemic stroke, systemic embolism, symptomatic intracranial hemorrhage, severe extracranial bleeding): 382 events were recorded in 375 patients.

	<b>With combined outcome (N=375)</b>	<b>Without combined outcome (N=3071)</b>	<b>p</b>
Age, years - mean (median)	78.0±9.1 (79)	76.2±9.8 (77)	0.01
Male sex	190 (50.7%)	1460 (47.5%)	0.2
Diabetes mellitus	120 (32.0%)	719 (23.4%)	<0.0001
Hypertension	332 (88.5%)	2445 (79.6%)	<0.0001
Hyperlipidemia	174 (46.4%)	1227 (39.9%)	0.02
Paroxysmal AF	160 (42.7%)	1375 (44.8%)	0.4
History of stroke/TIA	127 (33.9%)	912 (29.7%)	0.1
Current smoker	93 (24.8%)	587 (19.1%)	0.01
Alcoholism	29 (7.7%)	227 (7.4%)	0.7
History of myocardial infarction	82 (21.9%)	533 (17.4%)	0.04
Leukoaraiosis	230 (61.3%)	1653 (53.8%)	0.007
Oral anticoagulant therapy	295 (78.7%)	2568 (86.5%)	<0.0001
Statin therapy	150 (40.0%)	1008 (32.8%)	0.008
Antiplatelet associated with oral anticoagulant	81 (21.6%)	326 (10.6%)	<0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc > 3	328 (87.5%)	2602 (84.7%)	0.1
EF ≤ 40%	86 (22.9%)	552 (18.0%)	0.02

**Table S2.** Characteristics of the patients with ischemic event (ischemic stroke and systemic embolism).

	<b>With ischemic event (N=230)</b>	<b>Without ischemic event (N=3247)</b>	<b>p</b>
Age, years - mean (median)	78.2±9.3 (80)	76.2±9.8 (77)	0.03
Male sex	113 (49.1%)	1537 (47.3%)	0.7
Diabetes mellitus	75 (32.6%)	764 (23.5%)	0.004
Hypertension	204 (88.7%)	2573 (79.2%)	0.001
Hyperlipidemia	108 (46.9%)	1293 (39.8%)	0.05
Paroxysmal AF	95 (41.3%)	1440 (44.3%)	0.3
History of stroke/TIA	87 (37.8%)	952 (29.3%)	0.01
Current smoker	60 (26.1%)	620 (19.1%)	0.01
Alcoholism	17 (7.4%)	239 (7.4%)	1.0
History of myocardial infarction	53 (23.0%)	562 (17.3%)	0.04
Leukoaraiosis	141 (61.3%)	1742 (53.6%)	0.03
Oral anticoagulant therapy	185 (80.4%)	2768 (85.2%)	0.03
Statin therapy	95 (41.3%)	1063 (32.7%)	0.01
Antiplatelet associated with oral anticoagulant	50 (21.7%)	357 (11.0%)	<0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc > 3	203 (88.3%)	2727 (84.0%)	0.1
EF ≤ 40%	58 (25.2%)	580 (17.9%)	0.01

**Table S3.** Characteristics of the patients with hemorrhagic event (symptomatic intracranial hemorrhage and severe extracranial bleeding).

	<b>With hemorrhagic event (N=152)</b>	<b>Without hemorrhagic outcome (N=3325)</b>	<b>p</b>
Age, years - mean (median)	78.0±8.6 (79)	76.2±9.8 (77)	0.1
Male sex	82 (53.9%)	1568 (47.2%)	0.1
Diabetes mellitus	46 (30.3%)	793 (23.8%)	0.1
Hypertension	133 (87.5%)	2644 (79.5%)	0.03
Hyperlipidemia	68 (44.7%)	1333 (40.1%)	0.3
Paroxysmal AF	65 (42.8%)	1470 (44.2%)	0.6
History of stroke/TIA	39 (25.7%)	1000 (30.1%)	0.2
Current smoker	32 (21.0%)	648 (19.5%)	0.6
Alcoholism	14 (9.2%)	242 (7.3%)	0.2
History of myocardial infarction	31 (20.4%)	584 (17.6%)	0.3
Leukoaraiosis	95 (62.5%)	1788 (53.8%)	0.05
Oral anticoagulant therapy	113 (74.3%)	2840 (85.4%)	<0.0001
Statin therapy	56 (36.8%)	1102 (33.1%)	0.4
Antiplatelet associated with oral anticoagulant	32 (21.1%)	375 (11.3%)	0.001
CHA <sub>2</sub> DS <sub>2</sub> VASc > 3	132 (86.8%)	2798 (84.2%)	0.6
EF ≤ 40%	29 (19.1%)	609 (18.3%)	0.8

**Table S4.** Characteristics of the patients with EF  $\leq$  40% treated with NOACs or with vitamin K antagonists.

	<b>NOAC (N=421)</b>	<b>Vitamin K antagonist (N=129)</b>	<b>p</b>
Age, years - mean (median)	77.4 $\pm$ 10.5 (80)	74.6 $\pm$ 10.1 (77)	0.02
NIHSS, mean (median)	7.7 $\pm$ 5.6 (6)	8.1 $\pm$ 6.7 (6)	0.04
Male sex	224 (53.2%)	70 (54.3%)	0.8
Diabetes mellitus	127 (30.2%)	40 (31.0%)	0.9
Hypertension	350 (83.1%)	109 (84.4%)	0.8
Hyperlipidemia	196 (46.5%)	55 (42.6%)	0.4
Paroxysmal AF	141 (33.5%)	33 (25.6%)	0.08
History of stroke/TIA	141 (33.5%)	39 (30.2%)	0.6
Current smoker	93 (22.1%)	10 (7.8%)	<0.0001
Alcoholism	45 (10.7%)	16 (12.4%)	0.6
History of myocardial infarction	148 (35.2%)	41 (31.8%)	0.4
Leukoaraiosis	278 (66.0%)	56 (43.4%)	<0.0001
Antiplatelet associated with oral anticoagulant	27 (6.4%)	36 (27.9%)	<0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc > 3	386 (91.7%)	122 (94.6%)	0.3
Combined endpoint	47 (11.2%)	26 (20.2%)	0.02
Ischemic endpoint	32 (7.6%)	17 (13.2%)	0.07
Hemorrhagic endpoint	14 (3.3%)	9 (7.0%)	0.08